The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The companies clash over survival curve similarities – and differences.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Petosemtamab's phase 2 data in this setting should come by the year end.
After ZW171's exit, ZW251 enters the clinic.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.